Taxus Cardium Pharmaceuticals Group Inc. and its operating unit Activation Therapeutics announced that a Notice of Allowance has been received from the U.S. Patent and Trademark Office for a new patent application (U.S. Application No. 13/648,255) entitled "Flowable Formulations for Tissue Repair and Regeneration. The patent application includes claims covering methods to utilize formulations encompassing Excellagen [2.6%] as a topically applied flowable fibrillar collagen matrix for wound repair by promoting localized release of platelet derived growth factors and providing an in situ microstructural scaffold for cell migration. Excellagen is an FDA-cleared, aseptically manufactured, syringe-based, skin substitute wound care dressing consisting of a stabilized formulation of renatured atelopeptide bovine fibrillar tropocollagen that is designed for professional use. Excellagen, and related formulations covered by the patent application, are designed to possess key structural and biological functions to effectively promote wound repair and tissue regeneration, and also provides a platform technology for delivery of a variety of biologics and wound healing agents for tissue repair and regeneration. In accordance with the FDA-cleared instructions for use, Excellagen is applied topically to a chronic dermal wound immediately following surgical debridement, a standard practice used by medical professionals to remove necrotic tissue, resulting in a bleeding wound bed. As covered in the U.S. patent, the application of Excellagen following debridement, in the presence of a small amount of blood, promotes platelet activation and endogenous release of key wound healing growth factors, including platelet derived growth factor-BB (PDGF-BB). The PDGF-BB protein is the active ingredient of becaplermin gel [0.01%] (tradename Regranex) which is FDA approved for the treatment of lower extremity diabetic neuropathic ulcers.